U.S. BIOCHIP PRODUCT AND SERVICES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

U.S. Biochip Product And Services Market is estimated to be valued at USD 10.30 Bn in 2026 and is expected to reach USD 21.13 Bn in 2033, exhibiting a compound annual growth rate (CAGR) of 10.8% from 2026 to 2033.

Analysts’ Views on U.S. Biochip Product & Services Market:

Biochip Products are used for diagnosis of infectious diseases, respiratory diseases, cancer, and for personalized treatment. There are three types of biochips namely DNA microarray, protein microarray, and microfluidic chip. Increasing number of clinical trials along with technological advancements of biochips are expected to aid in the growth of the market. Furthermore, increasing product approvals and increasing incidence of chronic diseases is also expected to assist the growth of the market during the forecasted period.

Figure 1. U.S. Biochip Product & Services Market Share (%), by Product Type, 2026

U.S. Biochip Product & Services Market – Driver

Increasing approval of drugs in the U.S.

Increasing approval of drugs in the U.S. Is expected to propel growth of the U.S. biochip product & services market over the forecast period. For instance, according to Pharmaceutical Research and Manufacturers of America on February 13, 2023, Reported the FDA approved 257 new drugs, including 127 (49.4%) orphan and 130 (50.6%) non-orphan drugs in 2017–2021.

Increasing number of clinical trials

Increasing number of clinical trials for biochip products is also expected to aid in the growth of the market. Clinical studies are an important part of drug development in the U.S. The number of registered clinical trials has increased significantly in recent years. For instance, according to the U.S. National Library of Medicine in July 2022, the number of clinical trials conducted in the U.S. increased from 17,978 in 2020 to 22,342 in 2021.

Figure 2. . U.S. Biochip Product & Services Market Share (%), by Application, 2026

U.S.

Biochip Product & Services market. healthcare system.

U.S. Biochip Product & Services Market Segmentation:

The U.S. Biochip Product & Services market report is segmented into By Type and Application,

By Type, the market is segmented into Products (Microarrays, Reagents & other Consumables, Others) & Services. Out of which, the Products (Microarrays, Reagents & other Consumables, Others) segment is expected to hold a dominant position in the U.S. Biochip Product & Services market during the forecast period and this is attributed to measure the relative concentration of nucleic acid sequences in a mixture via hybridization and subsequent detection of the hybridization events.

By Application, the market is segmented Drug Discovery, Life Science Research, IVD Tests, and Others. Out of which, the Drug Discovery segment is expected to hold a dominant position in the U.S. biochip product & services market during the forecast period and this is attributed to the increasing research and development in the field of U.S. biochip products.

U.S. Biochip Product & Services Market: Key Developments

On May 18, 2023, Abbott Laboratories, an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, U.S., announced its Assert-IQ insertable cardiac monitor (ICM) biochip has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats. This clearance builds on Abbott's portfolio of connected health devices that can better help doctors manage and treat their patients remotely.

On June 6, 2023, Agilent Technologies Inc., a medical company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories, announced the release of the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell analysis data. This improved version enables Agilent xCELLigence Real-Time Cell Analysis (RTCA) systems in GMP-regulated facilities.

In December 2022, Pulmostics Limited is developing a diagnostic system that detects early breast cancer based on Breath Analysis in the U.S., announced that in conjunction with the prestigious CHRISTUS Muguerza Alta Especialidad Hospital and the CHRISTUS CEI Clinical Research Center in Monterrey, Nuevo León, México, has begun a clinical trial to validate the use of a Pulmostics Limited breath to detect breast cancer in women.

On March 09, 2023, Agilent Technologies Inc., a medical company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories, announced the acquisition of e-MSion, an early-stage company behind the innovative electron capture dissociation (ECD) technology known as the ExD cell.

In March 2022, U.S. startup Nutcracker Therapeutics raises US$ 167 million for the advancement of its mRNA biochip-based manufacturing platform. In May 2021, TU Wien, which is a major university in Austria developed a biochip that could be used to produce tissue beads in the desired size and supply them with drugs or nutrients.

U.S. Biochip Product & Services Market: Key Trends

Biochip products can find applications in allergy diagnostics

Biochip products can find application in allergy diagnostics and is expected to propel the growth of the U.S. Biochip Product & Services market over the forecast period. For instance, in April 2020, researchers from the Technical University of Munich reported the use of Immuno Solid phase Allergen Chip (ISAC) for nasal fluid as a noninvasive sampling method as allergy screening test.

U.S. Biochip Product & Services Market: Restraint

Low commercial acceptability of biochips due to their high cost

Low commercial acceptability of biochips due to their high cost is expected to hinder the growth of the market. The manufacturing process of biochips requires specialized techniques of surface chemistry. The process also requires highly sophisticated devices such as integrated electronic devices and micromechanical devices. These devices are expensive, in terms of both purchasing as well as handling costs. For instance, in October 2020, AYOXXA Biosystems GmbH is a biotechnology company,  launched LUNARISTM Chemokine Kits for the exploration of human (Human 11-Plex) and murine (Mouse-12-Plex) chemokine signaling pathways. The retail price of a single human biochip cost around US$ 400 to US$ 500.

Market Players are taking initiatives to launch cost-effective products.

U.S. Biochip Product & Services Market - Key Players

Major players operating in the U.S. Biochip Product & Services market include Abbott Laboratories, Agilent Technologies, Affymetrix Inc., Beckman Coulter, Inc., Illumina Incorporated, Life Technologies Corporation, Randox Laboratories Ltd., Surfix B.V, GE Healthcare, F. Hoffmann-La Roche Ltd and AYOXXA Biosystems GmbH.

*Definition: Biochips are miniaturized laboratories used to conduct several simultaneous biochemical reactions. A biochip comprises mainly three types: DNA microarray, protein microarray, and microfluidic chip. Biochips are used to detect and quantify molecular complexes.